These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 26441497)

  • 1. From UBE3A to Angelman syndrome: a substrate perspective.
    Sell GL; Margolis SS
    Front Neurosci; 2015; 9():322. PubMed ID: 26441497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel UBE3A sequence variant identified in eight related individuals with neurodevelopmental delay, results in a phenotype which does not match the clinical criteria of Angelman syndrome.
    Geerts-Haages A; Bossuyt SNV; den Besten I; Bruggenwirth H; van der Burgt I; Yntema HG; Punt AM; Brooks A; Elgersma Y; Distel B; Valstar M
    Mol Genet Genomic Med; 2020 Nov; 8(11):e1481. PubMed ID: 32889787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UBE3A: The Role in Autism Spectrum Disorders (ASDs) and a Potential Candidate for Biomarker Studies and Designing Therapeutic Strategies.
    Roy B; Amemasor E; Hussain S; Castro K
    Diseases; 2023 Dec; 12(1):. PubMed ID: 38248358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuronal overexpression of Ube3a isoform 2 causes behavioral impairments and neuroanatomical pathology relevant to 15q11.2-q13.3 duplication syndrome.
    Copping NA; Christian SGB; Ritter DJ; Islam MS; Buscher N; Zolkowska D; Pride MC; Berg EL; LaSalle JM; Ellegood J; Lerch JP; Reiter LT; Silverman JL; Dindot SV
    Hum Mol Genet; 2017 Oct; 26(20):3995-4010. PubMed ID: 29016856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypersociability in the Angelman syndrome mouse model.
    Stoppel DC; Anderson MP
    Exp Neurol; 2017 Jul; 293():137-143. PubMed ID: 28411125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc.
    Greer PL; Hanayama R; Bloodgood BL; Mardinly AR; Lipton DM; Flavell SW; Kim TK; Griffith EC; Waldon Z; Maehr R; Ploegh HL; Chowdhury S; Worley PF; Steen J; Greenberg ME
    Cell; 2010 Mar; 140(5):704-16. PubMed ID: 20211139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Autism and Angelman Syndrome Protein Ube3A/E6AP: The Gene, E3 Ligase Ubiquitination Targets and Neurobiological Functions.
    Khatri N; Man HY
    Front Mol Neurosci; 2019; 12():109. PubMed ID: 31114479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deleting a UBE3A substrate rescues impaired hippocampal physiology and learning in Angelman syndrome mice.
    Sell GL; Xin W; Cook EK; Zbinden MA; Schaffer TB; O'Meally RN; Cole RN; Margolis SS
    Sci Rep; 2021 Sep; 11(1):19414. PubMed ID: 34593829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UBE3A and Its Link With Autism.
    Vatsa N; Jana NR
    Front Mol Neurosci; 2018; 11():448. PubMed ID: 30568575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A placebo-controlled trial of folic acid and betaine in identical twins with Angelman syndrome.
    Han J; Bichell TJ; Golden S; Anselm I; Waisbren S; Bacino CA; Peters SU; Bird LM; Kimonis V
    Orphanet J Rare Dis; 2019 Oct; 14(1):232. PubMed ID: 31640736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and Characterization of a Novel Angelman Syndrome Mouse Model with a Full Deletion of the
    Syding LA; Kubik-Zahorodna A; Nickl P; Novosadova V; Kopkanova J; Kasparek P; Prochazka J; Sedlacek R
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angelman syndrome: advancing the research frontier of neurodevelopmental disorders.
    Philpot BD; Thompson CE; Franco L; Williams CA
    J Neurodev Disord; 2011 Mar; 3(1):50-6. PubMed ID: 21484597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autism-linked UBE3A gain-of-function mutation causes interneuron and behavioral phenotypes when inherited maternally or paternally in mice.
    Xing L; Simon JM; Ptacek TS; Yi JJ; Loo L; Mao H; Wolter JM; McCoy ES; Paranjape SR; Taylor-Blake B; Zylka MJ
    Cell Rep; 2023 Jul; 42(7):112706. PubMed ID: 37389991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential therapeutic approaches for Angelman syndrome.
    Bi X; Sun J; Ji AX; Baudry M
    Expert Opin Ther Targets; 2016; 20(5):601-13. PubMed ID: 26558806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel variant in UBE3A in a family with multigenerational intellectual disability and developmental delay.
    Zhao X; Zheng Y; Wang L; Wang Y; Mei S; Kong X
    Mol Genet Genomic Med; 2022 Apr; 10(4):e1883. PubMed ID: 35225435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.
    Meng L; Ward AJ; Chun S; Bennett CF; Beaudet AL; Rigo F
    Nature; 2015 Feb; 518(7539):409-12. PubMed ID: 25470045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angelman syndrome - insights into a rare neurogenetic disorder.
    Buiting K; Williams C; Horsthemke B
    Nat Rev Neurol; 2016 Oct; 12(10):584-93. PubMed ID: 27615419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Origin and Evolution of the Angelman Syndrome Ubiquitin Ligase Gene
    Sato M
    Front Cell Neurosci; 2017; 11():62. PubMed ID: 28326016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UBE3A-mediated PTPA ubiquitination and degradation regulate PP2A activity and dendritic spine morphology.
    Wang J; Lou SS; Wang T; Wu RJ; Li G; Zhao M; Lu B; Li YY; Zhang J; Cheng X; Shen Y; Wang X; Zhu ZC; Li MJ; Takumi T; Yang H; Yu X; Liao L; Xiong ZQ
    Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12500-12505. PubMed ID: 31160454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Cerebral Organoids Reveal Early Spatiotemporal Dynamics and Pharmacological Responses of UBE3A.
    Sen D; Voulgaropoulos A; Drobna Z; Keung AJ
    Stem Cell Reports; 2020 Oct; 15(4):845-854. PubMed ID: 32916124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.